Education
About Us
Working with TipRanks
Follow Us
ProMIS Neurosciences (PMN)
NASDAQ:PMN
PMN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.62 - $2.61
Previous CloseN/A
Volume32.49K
Average Volume (3M)45.56K
Market Cap
$25.17M
Enterprise Value$16.01M
Total Cash (Recent Filing)$2.39M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Mar 14, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding32,689,190
10 Day Avg. Volume47,416
30 Day Avg. Volume45,559
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.53
Enterprise Value/Ebitda5.38
Forecast
1Y Price Target
$7.00Price Target Upside809.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
ProMIS Neurosciences News
PremiumPre-Earnings
Is PMN a Buy, Before Earnings?
PremiumCompany Announcements
ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial
PremiumCompany Announcements
ProMIS Neurosciences Announces COO Position Termination
PremiumCompany Announcements
ProMIS Neurosciences Highlights Neurodegenerative Disease Focus
PremiumCompany Announcements
ProMIS Neurosciences Launches Phase 1b Trial for Alzheimer’s---
Bulls Say, Bears Say
Bulls Say
Dosing EfficiencyThe half-life of PMN310 was determined to be approximately 25 days, which supports once-per-month dosing, enhancing patient convenience and compliance.
Financial PositionThe recently completed PIPE financing provides an initial upfront funding of $30.3M with the potential for an additional $92.4M, boosting the company's financial resources.
Safety And TolerabilityPMN310 demonstrated a favorable safety and tolerability profile with no treatment-emergent serious adverse events observed.
Bears Say
Cash ReservesThe company finished with only $1.0M in cash and cash equivalents, a concern for ongoing operational expenses.
Complexity In Targeting TDP-43Targeting TDP-43 involves complex dosing determinations due to its essential role in cells and its involvement in multiple conditions, posing potential challenges in treatment development.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PMN FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was $0.62 and its highest was $2.61 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is $25.17M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is Mar 14, 2025 which is in 2 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on Nov 14, 2024. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of -$0.068 by $0.378.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -0.14.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 32,689,190 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of $0.31 in its last earnings report, beating expectations of -$0.068. Following the earnings report the stock price went up 1.02%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in PMN
---
ProMIS Neurosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (809.09% Upside)
$7.00 (809.09% Upside)
Insider Transactions
Bought Shares
Worth $14.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.60%
12-Months-Change
Fundamentals
Return on Equity
-8.03%
Trailing 12-Months
Asset Growth
37.11%
Trailing 12-Months
Company Description
ProMIS Neurosciences
ProMIS Neurosciences Inc is a biotech company. It is engaged in discovering and developing precision medicine therapeutics for the effective treatment of neurodegenerative diseases, in particular, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD).
---
PMN Stock 12 Month Forecast
Average Price Target
$7.00
▲(809.09% Upside)
Technical Analysis
Best Analysts Covering PMN
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-35.50%
reiterated a buy rating 2 months ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -35.50% per trade.
---